San Diego, CA - Linagliptin (Tradjenta, Boehringer Ingelheim) shows similar efficacy to glimepiride (Amaryl, Sanofi-Aventis) for the treatment of patients with type 2 diabetes, in terms of controlling ...

The new analyses show linagliptin, alone or in combination with other diabetes therapies, lowered hemoglobin A1c (HbA1c or A1C) in elderly patients with type 2 diabetes, as well as in adults with type ...

Sulfonylureas are often added to metformin to improve glycemic control, but at the known risk of increasing hypoglycemia and weight gain. In a report published in the Lancet, more than 1,500 patients ...

SAN DIEGO, California — Linagliptin appears to have nephroprotective effects when used in the treatment of type 2 diabetes mellitus (T2DM). Maximilian von Eynatten, MD, executive medical director for ...

Review the side-effects of Linagliptin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

New treatment combines DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta™ (linagliptin) tablets), and metformin in a single tablet, taken twice-daily, to lower blood sugar in adults ...

Discover comprehensive details about Linagliptin, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Boehringer Ingelheim announced results from its four Phase 3 trials of linagliptin for the treatment of type 2 diabetes. The aim of the four, 24-week, international, randomized, double-blind, ...

RIDGEFIELD, Conn., and INDIANAPOLIS, March 23, 2015 /PRNewswire/ -- Glyxambi® (empagliflozin/linagliptin) tablets are now available by prescription in many leading ...

Boehringer Ingelheim (BI) has released a fistful of data from Phase III clinical trials showing that the DPP-4 inhibitor linagliptin, the most advanced compound in the company’s diabetes portfolio, ...